Temsirolimus

被引：32

作者：

Rini, Brian

Kar, Santwana

Kirkpatrick, Peter

机构：

[1] Cleveland Clin, Taussig Canc Ctr, Dept Solid Tumor Oncol & Urol, Cleveland, OH 44195 USA

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2007年 / 6卷 / 08期

关键词：

D O I：

10.1038/nrd2382

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Temsirolimus (Torisel; Wyeth) is an inhibitor of the kinase mTOR (mammalian target of rapamycin). It was approved by the US FDA for the treatment of advanced renal cell carcinoma in May 2007.

引用

页码：599 / 600

页数：2

共 14 条

[11] Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer [J].

Raymond, E ;

Alexandre, J ;

Faivre, S ;

Vera, K ;

Materman, E ;

Boni, J ;

Leister, C ;

Korth-Bradley, J ;

Hanauske, A ;

Armand, JP .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2336-2347

[12]

Skotnicki JS, 2001, CLIN CANCER RES, V7, p3749S

[13] Discovery and development of sorafenib: a multikinase inhibitor for treating cancer [J].

Wilhelm, Scott ;

Carter, Christopher ;

Lynch, Mark ;

Lowinger, Timothy ;

Dumas, Jacques ;

Smith, Roger A. ;

Schwartz, Brian ;

Simantov, Ronit ;

Kelley, Susan .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (10) :835-844

[14] A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [J].

Yang, JC ;

Haworth, L ;

Sherry, RM ;

Hwu, P ;

Schwartzentruber, DJ ;

Topalian, SL ;

Steinberg, SM ;

Chen, HX ;

Rosenberg, SA .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) :427-434

← 1 2 →